Human RCTPubMed ID: 30602409·2019

PIONEER 1: Oral Semaglutide Efficacy in Type 2 Diabetes

Pratley RE, Aroda VR, Lingvay I, et al.

Diabetes Care, 2019 · n = 723

Key finding

Oral semaglutide 14mg daily reduced HbA1c by 1.5% compared to placebo, achieved 70% with A1c <7%, and produced 4.4kg mean weight loss.

Summary

Phase 3b trial of oral semaglutide showing significant HbA1c reduction and weight loss in patients with type 2 diabetes.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaglutideL5

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.

More research on Semaglutide

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

New England Journal of Medicine · 2023 · Human RCT

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

New England Journal of Medicine · 2023 · Human RCT

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)

Nature Medicine · 2022 · Human RCT

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)

JAMA · 2022 · Human RCT

STEP 3: Semaglutide for Weight Management in Severe Obesity

New England Journal of Medicine · 2022 · Human RCT